CLOs on the Move

SI Bone

www.si-bone.com

 
SI-BONE, Inc. (San Jose, California) is the leading sacroiliac joint medical device company dedicated to the development of tools and products for patients with low back issues related to certain SI joint disorders. The company has developed, and is manufacturing and marketing, minimally invasive products for patients with certain SI joint disorders. SI-BONE has an experienced management team with extensive experience in orthopedic and spine medical devices.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.si-bone.com
  • 3055 Olin Ave3055 Olin Avenue Suite 2200
    San Jose, CA USA 95128
  • Phone: 408.207.0700

Executives

Name Title Contact Details

Similar Companies

Arbor Hospice and Home Care

Arbor Hospice & Home Care is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Ann Arbor, MI. To find more information about Arbor Hospice & Home Care, please visit www.arborhospice.org

Pascal Metrics

Pascal Metrics is the preeminent provider in the healthcare industry of real-time patient safety and clinical improvement services to reduce patient harm and related cost.

WellCheck Inc

WellCheck Inc is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Behavioral Healthcare Options

Behavioral Healthcare Options is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProKidney

ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III